Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
Belite Bio initiated rolling FDA NDA submission for Timlarebant in Stargardt disease, targeting completion by Q2 2026, and fully enrolled its Phase II/III DRAGON2 trial. In Q1 2026, GAAP net loss widened to $26.9 million on R&D spending of $15.7 million, with cash and equivalents of $799 million.
1. Regulatory Progress
Belite Bio has started rolling submission of its NDA for Timlarebant in Stargardt disease with the FDA, aiming to complete by Q2 2026, while also finalizing enrollment in the Phase II/III DRAGON2 registration trial for Japan.
2. Q1 Financial Results
The company reported a GAAP net loss of $26.9 million for Q1 2026, up from $14.3 million year-over-year, driven by a 67% increase in R&D spending to $15.7 million and SG&A expenses rising to $17 million.
3. Cash Position and Commercial Preparation
Belite Bio held $799 million in cash and equivalents at quarter end, has recruited its full commercial leadership team and is engaging the retinal community to prepare for a potential Timlarebant launch, while evaluating pricing between $350,000 and $500,000 per treatment.